PMID- 16633299
OWN - NLM
STAT- MEDLINE
DCOM- 20060830
LR  - 20220311
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 30
IP  - 3
DP  - 2006 Mar
TI  - Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic 
      adenocarcinoma. Results of a phase II trial.
PG  - 357-63
AB  - BACKGROUND: The efficacy and benefit of second-line chemotherapy in advanced 
      pancreatic adenocarcinoma has never been demonstrated although it is regularly 
      used. PATIENTS AND METHODS: A randomized phase II study evaluating oxaliplatin 
      alone (OXA), infusional 5-fluorouracil alone (5-FU) and an oxaliplatin/infusional 
      5-FU combination (OXFU) in untreated advanced pancreatic adenocarcinoma has been 
      conducted. In this trial, a second-line treatment with the OXFU regimen (OXA 130 
      mg/m2 2-h intravenous (i.v.) infusion combined with 5-FU (1000 mg/m2/day, 
      continuous i.v., days 1-4), every 3 weeks) was offered to patients progressing 
      after single agent treatment. RESULTS: Eighteen out of 32 patients (12 males, 
      median age 57 years) treated in the single agent arms received the OXFU 
      combination in second-line treatment. WHO performance status was at least 2 in 
      61% of the patients. There was no objective response and 3 patients (17%) had a 
      disease stabilisation. Median time to progression from the start of second-line 
      treatment was 0.9 months. Median overall survival was 4.9 months from the start 
      of front-line therapy and 1.3 months from the start of second-line therapy. 
      CONCLUSION: The results of this trial bring arguments to support a modest value 
      of second-line chemotherapy for advanced pancreatic adenocarcinoma.
FAU - Mitry, Emmanuel
AU  - Mitry E
AD  - CHU Ambroise Pare, Boulogne. emmanuel.mitry@apr.aphp.fr
FAU - Ducreux, Michel
AU  - Ducreux M
FAU - Ould-Kaci, Mahmoud
AU  - Ould-Kaci M
FAU - Boige, Valerie
AU  - Boige V
FAU - Seitz, Jean-Francois
AU  - Seitz JF
FAU - Bugat, Roland
AU  - Bugat R
FAU - Breau, Jean-Luc
AU  - Breau JL
FAU - Bouche, Olivier
AU  - Bouche O
FAU - Etienne, Pierre-Luc
AU  - Etienne PL
FAU - Tigaud, Jean-Marie
AU  - Tigaud JM
FAU - Morvan, Francois
AU  - Morvan F
FAU - Cvitkovic, Esteban
AU  - Cvitkovic E
FAU - Rougier, Philippe
AU  - Rougier P
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - 0 (Organoplatinum Compounds)
RN  - 04ZR38536J (Oxaliplatin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adenocarcinoma/*drug therapy
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Disease Progression
MH  - Female
MH  - Fluorouracil/administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Organoplatinum Compounds/administration & dosage
MH  - Oxaliplatin
MH  - Pancreatic Neoplasms/*drug therapy
EDAT- 2006/04/25 09:00
MHDA- 2006/08/31 09:00
CRDT- 2006/04/25 09:00
PHST- 2006/04/25 09:00 [pubmed]
PHST- 2006/08/31 09:00 [medline]
PHST- 2006/04/25 09:00 [entrez]
AID - s0399-8320(06)73188-8 [pii]
AID - 10.1016/s0399-8320(06)73188-8 [doi]
PST - ppublish
SO  - Gastroenterol Clin Biol. 2006 Mar;30(3):357-63. doi: 
      10.1016/s0399-8320(06)73188-8.